Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
28 studies found for:    omalizumab, urticaria
Show Display Options
RSS Create an RSS feed from your search for:
omalizumab, urticaria
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment
Condition: CHRONIC SPONTANEOUS URTICARIA
Intervention: Drug: OMALIZUMAB
2 Unknown  Efficacy and Safety of Omalizumab in Patients With Severe Acute Urticaria
Condition: Urticaria
Intervention: Drug: omalizumab
3 Completed
Has Results
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
Condition: Chronic Urticaria
Interventions: Drug: Omalizumab 75-375 mg;   Drug: Placebo to omalizumab;   Drug: Loratadine;   Drug: Clemastine
4 Recruiting Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria
Condition: Chronic Idiopathic Urticaria
Intervention: Biological: Xolair
5 Completed Omalizumab in Severe and Refractory Solar Urticaria
Condition: Solar Urticaria
Intervention: Drug: Omalizumab
6 Recruiting Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation
Condition: Urticaria
Interventions: Dietary Supplement: Vitamin D (4,000 IU/day);   Dietary Supplement: Vitamin D (400 IU/day);   Drug: Omalizumab
7 Active, not recruiting Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria
Condition: Chronic Urticaria
Intervention: Drug: Omalizumab
8 Completed
Has Results
Cold Urticaria Treatment With Xolair
Condition: Cold Contact Urticaria
Interventions: Drug: Omalizumab;   Drug: Placebo
9 Completed OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients
Condition: Chonic Spontaneous Urticaria
Intervention: Drug: omalizumab
10 Enrolling by invitation Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria
Condition: Chronic Urticaria
Interventions: Biological: Omalizumab;   Biological: Placebo
11 Completed
Has Results
A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: omalizumab;   Drug: placebo;   Drug: H1 antihistamines;   Drug: Diphenhydramine
12 Completed Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients
Conditions: Chronic Urticaria;   Chronic Idiopathic Urticaria;   Chronic Spontaneous Urticaria
Interventions: Drug: Omalizumab (Xolair);   Drug: Placebo
13 Unknown  Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria
Condition: Chronic Idiopathic Urticaria
Intervention: Drug: Omalizimab
14 Completed
Has Results
Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: IGE025;   Drug: placebo
15 Completed
Has Results
Urticaria Facticia Treatment With Omalizumab (UFO)
Condition: Symptomatic Dermographism
Interventions: Drug: Omalizumab;   Drug: Placebo
16 Completed
Has Results
A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: Omalizumab;   Drug: Placebo;   Drug: H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist;   Drug: Diphenhydramine
17 Active, not recruiting Efficacy Study of Omalizumab in Cholinergic Urticaria
Condition: Cholinergic Urticaria
Interventions: Biological: Active;   Biological: Placebo;   Biological: Open labeled
18 Completed Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy
Conditions: Chronic Spontaneous Urticaria;   Angioedema
Interventions: Biological: Omalizumab;   Drug: Placebo
19 Active, not recruiting A Study to Assess the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria (CIU)
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: Omalizumab;   Drug: Placebo
20 Completed
Has Results
A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: Omalizumab;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-28) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.